A Randomized Study to Evaluate the Efficacy and Adverse Effects of Cryotherapy Combined with Intralesional Steroids, Intralesional Bleomycin Combined with Steroids and Fractional CO(2) Laser in Keloids

一项随机研究评估了冷冻疗法联合病灶内注射类固醇、病灶内注射博来霉素联合类固醇和点阵二氧化碳激光治疗瘢痕疙瘩的疗效和不良反应

阅读:2

Abstract

BACKGROUND: Despite the availability of various treatment modalities, the treatment of keloids is often incomplete, with a high recurrence rate. The present study was undertaken to assess the efficacy and safety of cryotherapy combined with intralesional steroid injections (Cy + ILS), intralesional combined bleomycin and steroids (ILB + S), and fractional carbon dioxide laser (Fr CO(2)) in keloid management. PATIENTS AND METHODS: Ninety cases with keloids were enrolled and randomly divided into three groups of 30 patients each. The baseline severity of keloids was graded using the Vancouver scar scale (VSS) and high-frequency ultrasonography (HFUS). Group A, B, and C patients were treated with Cy + ILS, ILB + S, and Fr CO(2), respectively for four sittings at 4-week intervals. Improvement in VSS score was calculated after 4, 8, 12, and 16 weeks, and with HFUS after 16 weeks. At each visit, adverse effects, if any, were noted. Statistical analysis was done using Chi-square test and ANOVA. RESULTS: At the end of 16 weeks, the reductions in VSS in Cy + ILS, ILB + S, and Fr CO(2) groups were 5.12 (60.09%), 5.84 (69.30%), and 3.06 (38.3%), respectively (P = 0.00). The difference in mean VSS reduction after 16 weeks between ILB + S and Cy + ILS was not significant (P = 0.28), whereas ILB + S and Cy + ILS were more efficacious than Fr CO(2) (P = 0.01 and P = 0.02, respectively). The incidence of adverse effects was comparable between ILB + S and Fr CO(2) (P = 0.11) but higher with Cy + ILS (P = 0.04). LIMITATIONS: Small sample size, non-blinded design, and short follow-up period. CONCLUSION: ILB + S may be considered as the first-line treatment option for keloids in view of its satisfactory efficacy, and excellent safety profile.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。